Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of “Buy” from Brokerages

Revolution Medicines, Inc. (NASDAQ:RVMD) has earned a consensus recommendation of “Buy” from the twenty-one brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and five have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $78.9412.

Several equities research analysts have recently issued reports on RVMD shares. UBS Group initiated coverage on shares of Revolution Medicines in a report on Friday, February 27th. They issued a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Evercore raised shares of Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, February 25th. Wedbush restated an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. Finally, Truist Financial raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, March 25th.

Revolution Medicines Stock Performance

NASDAQ:RVMD opened at $98.64 on Friday. The firm has a market capitalization of $19.55 billion, a PE ratio of -16.69 and a beta of 0.99. The stock’s fifty day moving average is $99.06 and its 200 day moving average is $80.05. Revolution Medicines has a fifty-two week low of $29.17 and a fifty-two week high of $124.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period in the prior year, the firm earned ($1.12) EPS. On average, sell-side analysts anticipate that Revolution Medicines will post -3.49 earnings per share for the current year.

Insider Activity at Revolution Medicines

In related news, CFO Jack Anders sold 10,000 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total transaction of $980,000.00. Following the completion of the transaction, the chief financial officer owned 108,065 shares in the company, valued at $10,590,370. The trade was a 8.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Margaret A. Horn sold 75,000 shares of the company’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total value of $7,542,000.00. Following the completion of the transaction, the chief operating officer directly owned 141,053 shares in the company, valued at $14,184,289.68. This trade represents a 34.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 149,592 shares of company stock worth $15,010,732 over the last quarter. 8.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RVMD. Indiana Trust & Investment Management Co bought a new stake in Revolution Medicines during the 4th quarter valued at about $32,000. Global Retirement Partners LLC grew its stake in Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after acquiring an additional 361 shares in the last quarter. Torren Management LLC purchased a new position in shares of Revolution Medicines during the fourth quarter worth approximately $33,000. Arax Advisory Partners purchased a new position in shares of Revolution Medicines during the fourth quarter worth approximately $38,000. Finally, GAMMA Investing LLC raised its stake in shares of Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after acquiring an additional 260 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.